Janssen Biotech Inc.
800 Ridgeview Drive
Horsham
Pennsylvania
19044
United States
Tel: 888-227-5624
246 articles about Janssen Biotech Inc.
-
Aduro Biotech Meets Development Milestone In Immuno-Oncology Collaboration With Janssen Biotech Inc. For Treatment Of Prostate Cancer
2/9/2015
-
Janssen Biotech Inc. Release: U.S. FDA Approves IMBRUVICA® (ibrutinib) For The Treatment Of Waldenstrom's Macroglobulinemia: First FDA-Approved Therapy For This Disease
1/29/2015
-
Applied Molecular Transport Announces Research And Development Collaboration With Janssen Biotech Inc. And Johnson & Johnson Innovation For Novel Therapeutic Candidate To Treat Inflammatory Bowel Diseases
1/28/2015
-
Vectura Group plc Signs Global Development And Licence Agreement With Janssen Biotech Inc. In Asthma/COPD
1/6/2015
-
Geron Corporation Announces Early HSR Clearance For Global Strategic Collaboration With Janssen Biotech Inc.
12/16/2014
-
Atreca, Inc., Establishes Strategic Collaboration With Johnson & Johnson Innovation And Janssen Biotech Inc. To Apply Immune Repertoire Capture Technology To Autoimmune Disease
12/2/2014
-
Astellas Pharma Inc., Janssen Biotech Inc. To End Collaboration On RA Drug ASP015K
12/2/2014
-
IP Group plc – Modern Biosciences plc Announces Collaboration Worth Up To £176m With Johnson & Johnson Innovation And Janssen Biotech Inc.
12/1/2014
-
Genmab A/S Banks $10 Million Milestone Payment From Janssen Biotech Inc.
10/24/2014
-
Berkeley's Aduro Biotech Strikes $817 Million Lung Cancer Pact With Janssen Biotech Inc.
10/17/2014
-
Genmab A/S To Receive Milestone Payment In Duobody Platform Collaboration With Janssen Biotech Inc.
7/14/2014
-
Genmab A/S Reaches USD 25 Million Milestone In Daratumumab Collaboration With Janssen Biotech Inc.
7/7/2014
-
Johnson & Johnson's Janssen Biotech Inc. Licenses LADD From Bay Area's Aduro Biotech In Deal Worth $365 Million
5/30/2014
-
Negative National Institute for Clinical Excellence (NICE) Draft Guidance On Janssen Biotech Inc.'s Zytiga For Prostate Cancer
5/14/2014
-
FDA Approves Janssen Biotech Inc.'s SYLVANT For Rare Castleman's Disease
4/24/2014
-
Genmab A/S Reaches $22 Million Milestone In Daratumumab Collaboration With Janssen Biotech Inc.
3/27/2014
-
Amunix, Inc. Announces Expansion To Licensing Agreement With Janssen Biotech Inc. For Its Proprietary XTEN Technology
1/7/2014
-
Little Biotech, Capricor Therapeutics, Inc. Inks Heart Pact Worth $337.5 Million With Johnson & Johnson's Janssen Biotech Inc.
1/6/2014
-
Genmab A/S To Receive Milestone Payment In Duobody Platform Collaboration With Janssen Biotech Inc. – Financial Guidance Improved
12/6/2013
-
Genmab A/S Announces Expansion Of Duobody Platform Collaboration With Janssen Biotech Inc.
12/4/2013